AbbVie Inc. Depreciation & Amortization Growth

Depreciation & Amortization Growth of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation & Amortization Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Depreciation & Amortization Growth for the quarter ending September 29, 2021 was -7.2% (a -117.36% decrease compared to previous quarter)
  • Year-over-year quarterly Depreciation & Amortization Growth decreased by -102.36%
  • Annual Depreciation & Amortization Growth for 2020 was 220.82% (a 1446.36% increase from previous year)
  • Annual Depreciation & Amortization Growth for 2019 was 14.28% (a -18.82% decrease from previous year)
  • Annual Depreciation & Amortization Growth for 2018 was 17.59% (a -32.96% decrease from previous year)
  • Twelve month Depreciation & Amortization Growth ending September 29, 2021 was 75.12% (a -58.41% decrease compared to previous quarter)
  • Twelve month trailing Depreciation & Amortization Growth decreased by -65.98% year-over-year
Trailing Depreciation & Amortization Growth for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
75.12% 180.61% 292.04% 220.82%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation & Amortization Growth of AbbVie Inc.

Most recent Depreciation & Amortization Growthof ABBV including historical data for past 10 years.

Interactive Chart of Depreciation & Amortization Growth of AbbVie Inc.

AbbVie Inc. Depreciation & Amortization Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -7.2% 41.48% 296.24%
2020 305.7% 355.67% 209.76% 11.13% 220.82%
2019 15.16% 15.63% 13.32% 13.03% 14.28%
2018 19.78% 14.78% 16.89% 18.98% 17.59%
2017 12.5% 24.67% 31.14% 39.55% 26.24%
2016 25.67% 33.92% 52.11% 69.62% 42.22%
2015 35.23% 18.23% -5.94% -20.6% 6.36%
2014 -3.5% -17.95% -14.41% -12.33% -12.37%
2013 -35.28% 3.08% -20.0% -28.84% -22.0%
2012 -4.89% -27.99% -7.12% 1.44% -9.59%
2011 -72.57% -54.8% 7.43%
2010 69.75%

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.